Population Pharmacokinetic and Pharmacokinetic‐Pharmacodynamic Analysis for Clazakizumab in Patients With End‐Stage Kidney Disease Undergoing Dialysis
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70381 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Venkateswari Y Muthukrishnan und 8 weiteren Autor:innen. Beteiligte Einrichtung: CSL Behring LLC, King of Prussia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Renal Dialysis, Kidney Failure, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The inflammatory cytokine interleukin‐6 (IL‐6) plays a significant role in the progression of cardiovascular disease (CVD). We evaluated the impact of clazakizumab, a monoclonal antibody targeting the IL‐6 ligand, upon high‐sensitivity C‐reactive protein (hs‐CRP) as part of the dose‐finding phase 2b trial. In this randomized, double‐blind trial, adults with cardiovascular disease and/or diabetes receiving maintenance dialysis and having hs‐CRP ≥ 2 mg/L at baseline received clazakizumab (2.5 mg, 5 mg, or 10 mg, n = 32 per dose group) or placebo ( n = 31) every 4 weeks. These data were used to develop a population pharmacokinetics (popPK) and a longitudinal PK‐pharmacodynamic (PK‐PD) model to characterize the relationship between clazakizumab and hs‐CRP to support Phase 3 dose selection. A 2‐compartment model with linear elimination well described clazakizumab PK. PK‐PD was best described by an indirect‐response inhibitory model, where clazakizumab concentrations inhibited the k in (zero‐order rate of production) of hs‐CRP. Simulations predicted that all doses (2.5, 5, and 10 mg IV every 4 weeks) would result in the majority (> 80%) of subjects experiencing at least an 80% decrease in baseline hs‐CRP (80.9%, 83.4%, and 88.1%, respectively). In addition, the proportion of subjects with hs‐CRP concentrations below 2 mg/L at Week 12 was predicted to be 67.7%, 76.7%, and 82.6%, respectively, for these 3 dose groups. These modeling and simulation results support the dose selection of clazakizumab 5 mg IV every 4 weeks in the phase 3 placebo‐controlled trial to evaluate the impact of IL‐6 inhibition via clazakizumab administration upon cardiovascular events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CSL Behring LLC, King of Prussia, Pennsylvania, USA.
- Certara USA, Inc., Radnor, Pennsylvania, USA.
ORCID-Profile: Venkateswari Y Muthukrishnan, Laura E Strong, Marc Pfister, Anna Marie Chang, Jeannine S McCune
Zitieren
APA
Muthukrishnan, V. Y., Kerbusch, T., Strong, L. E., Kleijn, H. J., Pfister, M., Chang, A. M., Acharya, M., Nandy, P., & McCune, J. S. (2025). Population Pharmacokinetic and Pharmacokinetic‐Pharmacodynamic Analysis for Clazakizumab in Patients With End‐Stage Kidney Disease Undergoing Dialysis. Clinical and Translational Science. https://doi.org/10.1111/cts.70381
Vancouver
Muthukrishnan VY, Kerbusch T, Strong LE, Kleijn HJ, Pfister M, Chang AM, et al. Population Pharmacokinetic and Pharmacokinetic‐Pharmacodynamic Analysis for Clazakizumab in Patients With End‐Stage Kidney Disease Undergoing Dialysis. Clinical and Translational Science. 2025. doi:10.1111/cts.70381
BibTeX
@article{Muthukrishnan2025,
author = {Muthukrishnan, Venkateswari Y and Kerbusch, Thomas and Strong, Laura E and Kleijn, Huub Jan and Pfister, Marc and Chang, Anna Marie and Acharya, Milin and Nandy, Partha and McCune, Jeannine S},
title = {Population Pharmacokinetic and Pharmacokinetic‐Pharmacodynamic Analysis for Clazakizumab in Patients With End‐Stage Kidney Disease Undergoing Dialysis},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70381}
}
EUVIMED